Li Ping Wong1, Haridah Alias1, Pooi-Fong Wong2, Hai Yen Lee3, Sazaly AbuBakar3,4. 1. Centre for Epidemiology and Evidence-Based Practice, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya , Kuala Lumpur, Malaysia. 2. Department of Pharmacology, Faculty of Medicine, University of Malaya , Kuala Lumpur, Malaysia. 3. Tropical Infectious Diseases Research and Educational Centre (TIDREC), University of Malaya , Kuala Lumpur, Malaysia. 4. Department of Medical Microbiology, Faculty of Medicine, University of Malaya , Kuala Lumpur, Malaysia.
Abstract
BACKGROUND: The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. METHODS: A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP. RESULTS: A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes. CONCLUSIONS: The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP.
BACKGROUND: The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. METHODS: A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP. RESULTS: A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes. CONCLUSIONS: The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP.
Entities:
Keywords:
COVID-19 vaccination; Malaysia; health belief model; intention; willingness to pay
Authors: Noel T Brewer; Gretchen B Chapman; Frederick X Gibbons; Meg Gerrard; Kevin D McCaul; Neil D Weinstein Journal: Health Psychol Date: 2007-03 Impact factor: 4.267
Authors: Heidi J Larson; Alexandre de Figueiredo; Zhao Xiahong; William S Schulz; Pierre Verger; Iain G Johnston; Alex R Cook; Nick S Jones Journal: EBioMedicine Date: 2016-09-13 Impact factor: 8.143
Authors: Suzanna Awang Bono; Edlaine Faria de Moura Villela; Ching Sin Siau; Won Sun Chen; Supa Pengpid; M Tasdik Hasan; Philippe Sessou; John D Ditekemena; Bob Omoda Amodan; Mina C Hosseinipour; Housseini Dolo; Joseph Nelson Siewe Fodjo; Wah Yun Low; Robert Colebunders Journal: Vaccines (Basel) Date: 2021-05-17